Cybin Inc.

Cybin Inc. is a biopharmaceutical firm dedicated to advancing treatments derived from psychedelic compounds. Its active research and development portfolio features several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated form of dimethyltryptamine aimed at anxiety conditions; and CYB005, a phenethylamine derivative designed to address neuroinflammation. Additionally, Cybin has introduced EMBARK, a therapeutic approach incorporating psychedelic-assisted psychotherapy. The company's main operations are situated in Toronto, Canada.